beta

AKUS

Akouos, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Akouos, Inc. engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna in 2017 and is headquartered in Boston, MA.

Market Cap: 724 Million

Primary Exchange: NASDAQ

Website: http://www.akouos.com

Shares Outstanding: 32.5 Million

Float: 17.7 Million

Dividend: (%)

Beta: 0.550854252912

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 7 trading days

From: 2020-06-30 To: 2020-07-10

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud